BSE · 531569
Sanjivani Paranteral Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹19 Cr with net profit ₹2 Cr — a 11.82% net margin, versus 9.6% the period before.
Shareholding
As of 2026-09-30
- Promoter31.56%
- Public68.44%
5,774 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.94× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #24 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,73,334 Cr | 79.84 | 9.43 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹50,312 Cr | 43.91 | 4.86 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹43,233 Cr | 38.1 | 9.55 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹25,889 Cr | 89.83 | 20.09 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹18,228 Cr | 64.1 | 7.03 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹17,960 Cr | 26.99 | 5.33 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹16,307 Cr | 21.78 | 3.93 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,831 Cr | 26.77 | 4.57 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,899 Cr | 50.12 | 5.78 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹6,099 Cr | 48.26 | 6.53 | 12.36% | 18.59% |
| Sanjivani Paranteral Ltd.(this company) | ₹214 Cr | 28.71 | 4.44 | 13.87% | 10% |
AI analysis
AI-generated · google/gemini-2.5-flashSanjivani Paranteral Ltd. has a market capitalization of Rs 182 Cr. The company reported revenue of Rs 71.31 Cr and a net profit margin of 9.76%. Its Price-to-Earnings (PE) ratio is 27.12, and it has an EPS of 5.45. The company's debt-to-equity ratio stands at 0.14.
Positives
- +The debt-to-equity ratio is low at 0.14.
- +Promoter pledge is 0%, indicating no shares are pledged.
Negatives
- −Revenue decreased from Rs 20.86 Cr in Dec 2025 to Rs 10.51 Cr in Mar 2026 in the annual figures.
- −Net profit decreased from Rs 2.62 Cr in Dec 2025 to Rs 0.94 Cr in Mar 2026 in the annual figures.
- −Quarterly net profit decreased from Rs 2.78 Cr in Dec 2025 to Rs 0.55 Cr in Mar 2026.
- −The company's latest reported annual figures are from 'Mar 2026' but show lower values compared to previous quarters, suggesting these might be individual quarterly results rather than full annual data, leading to a lack of complete annual financial data.
- −No information on revenue growth is available.
Financial Performance
In the latest annual reporting period (Mar 2026), the company's revenue was Rs 10.51 Cr, with a net profit of Rs 0.94 Cr. Prior to that, in Dec 2025, revenue was Rs 20.86 Cr, and net profit was Rs 2.62 Cr. Quarterly revenue for Mar 2026 was Rs 13.21 Cr, yielding a net profit of Rs 0.55 Cr. This follows a December 2025 quarter where revenue reached Rs 22.06 Cr and net profit was Rs 2.78 Cr.
Profitability & Returns
Sanjivani Paranteral Ltd. generated a return on equity (ROE) of 13.87% and a return on capital employed (ROCE) of 16.287%. The company achieved a profit margin of 9.76% on its total revenue of Rs 71.31 Cr. The EPS for the period was 5.45.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.14, indicating a limited reliance on debt financing. The book value per share is reported as 39.27. No information on comprehensive assets or liabilities is provided in the available data.
Ownership & Pledges
As of June 30, 2026, promoter holding in Sanjivani Paranteral Ltd. was 31.5649%. Public shareholding was 62.9823%, and DIIs held 5.4528%. There are no reported pledged promoter shares. The number of shareholders is 5880 as of the latest disclosure.
Regulatory & Surveillance
There is no information available regarding any regulatory actions or surveillance measures concerning Sanjivani Paranteral Ltd.
Data as of — price: 2026-10-28 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.